Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.

@article{Russell1999CourseAC,
  title={Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.},
  author={James M. Russell and Ernst R. Berndt and Rosalba Miceli and Salvatore V. Colucci and Amy Nicole Grudzinski},
  journal={The American journal of managed care},
  year={1999},
  volume={5 5},
  pages={597-606}
}
OBJECTIVE To compare depression-related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline, paroxetine, or fluoxetine. PATIENTS AND METHODS Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995, following an antidepressant medication-free period of at least 6 months, were included. Treatment course and associated depression-related treatment and total healthcare… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995 , following an antidepressant medication - free period of at least 6 months , were included .
Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995 , following an antidepressant medication - free period of at least 6 months , were included .
Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995 , following an antidepressant medication - free period of at least 6 months , were included .
Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995 , following an antidepressant medication - free period of at least 6 months , were included .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Patients treated with paroxetine had shorter treatment duration ( 157.0 days ) than did patients treated with fluoxetine ( 192.6 days ) or sertraline ( 166.9 days , P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
During this study period when fluoxetine , paroxetine , and sertraline were all well - established agents , similar depression - related treatment courses and cost characteristics among all 3 drugs were observed .
Course and cost of treatment for depression with fluoxetine , paroxetine , and sertraline . OBJECTIVE .
Nine - hundred five ( 905 ) patients taking sertraline , 492 on paroxetine , and 945 on fluoxetine met inclusion criteria .
To compare depression - related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline , paroxetine , or fluoxetine .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Mean antidepressant prescription costs differed , being $ 586 , $ 419 , and $ 446 for fluoxetine , paroxetine and sertraline cohorts , respectively ( P < 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Patients receiving index treatment with paroxetine were most likely to switch to another SSRI ( 21.3% ) ; those taking sertraline were second most likely to switch ( 16.1% ) ; and those on fluoxetine were least likely ( 12.4% , P = 0.001 ) .
Claims records from a national database of patients diagnosed with depression who began treatment with an SSRI in 1995 , following an antidepressant medication - free period of at least 6 months , were included .
All Topics